Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Open access
Jacquelot, Nicolas, Yamazaki, Takahiro, Roberti, Maria P., Duong, Connie P. M., Andrews, Miles C., Verlingue, Loic, Ferrere, Gladys, Becharef, Sonia, Vétizou, Marie, Daillère, Romain, Messaoudene, Meriem, Enot, David P., Stoll, Gautier, Ugel, Stefano, Marigo, Ilaria, Foong Ngiow, Shin, Marabelle, Aurélien, Prevost-Blondel, Armelle, Gaudreau, Pierre-Olivier, Gopalakrishnan, Vancheswaran, Eggermont, Alexander M., Opolon, Paule, Klein, Christophe, Madonna, Gabriele, Ascierto, Paolo A., Sucker, Antje, Schadendorf, Dirk, Smyth, Mark J., Soria, Jean-Charles, Kroemer, Guido, Bronte, Vincenzo, Wargo, Jennifer, Zitvogel, Laurence · 2019 · Cell Research

Abstract

PD-1 blockade represents a major therapeutic avenue in anticancer immunotherapy. Delineating mechanisms of secondary resistance to this strategy is increasingly important. Here, we identified the deleterious role of signaling via the type I interferon (IFN) receptor in tumor and antigen presenting cells, that induced the expression of nitric oxide synthase 2 (NOS2), associated with intratumor accumulation of regulatory T cells (Treg) and myeloid cells and acquired resistance to anti-PD-1 monoclonal antibody (mAb). Sustained IFNβ transcription was observed in resistant tumors, in turn inducing PD-L1 and NOS2 expression in both tumor and dendritic cells (DC). Whereas PD-L1 was not involved in secondary resistance to anti-PD-1 mAb, pharmacological or genetic inhibition of NOS2 maintained long-term control of tumors by PD-1 blockade, through reduction of Treg and DC activation. Resistance to immunotherapies, including anti-PD-1 mAb in melanoma patients, was also correlated with the induction of a type I IFN signature. Hence, the role of type I IFN in response to PD-1 blockade should be revisited as sustained type I IFN signaling may contribute to resistance to therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41422-019-0224-x

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 256

Metadata

Authors
Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., Messaoudene, M., Enot, D. P., Stoll, G., Ugel, S., Marigo, I., Foong Ngiow, S., Marabelle, A., Prevost-Blondel, A., Gaudreau, P.-O., Gopalakrishnan, V., Eggermont, A. M., Opolon, P., Klein, C., Madonna, G., Ascierto, P. A., Sucker, A., Schadendorf, D., Smyth, M. J., Soria, J.-C., Kroemer, G., Bronte, V., Wargo, J., & Zitvogel, L.
Venue
Cell Research
Published
2019-09-03
Volume
29
Issue
10
Pages
846-861
ISSN
  • 1001-0602 (ISSN-L)
  • 1748-7838
OpenAlex
W2972096813
Cited by
256
References
65
FWCI
11.70
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. https://app.cochat.ai/papers/10.1038/s41422-019-0224-x
The paper
Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., Messaoudene, M., Enot, D. P., Stoll, G., Ugel, S., Marigo, I., Foong Ngiow, S., Marabelle, A., Prevost-Blondel, A., Gaudreau, P.-O., . . . Zitvogel, L. (2019). Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research. https://doi.org/10.1038/s41422-019-0224-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.